Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of 2.7%. Here, we discuss the reasons for the same. Strong Launch of SWTX's ...

SpringWorks Therapeutics (NASDAQ:SWTX) advanced 6.3% amid takeover speculation. The biotech firm is said to be at the center of renewed takeover speculation, according to a Betaville "uncooked" alert ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck KGaA has agreed to buy biotechnology company ...

SpringWorks Therapeutics Inc . (NASDAQ:SWTX), a biotechnology company with a market capitalization of $2.66 billion focused on developing targeted therapies for patients with severe rare diseases and ...

Springworks Therapeutics shares surged over 36% Monday, reaching levels last seen in mid-April 2022, as buyout speculation ...

6 analysts have expressed a variety of opinions on SpringWorks Therapeutics (NASDAQ:SWTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

Since we last visited SpringWorks Therapeutics, Inc. in the summer of 2023, the company has garnered its first FDA approval. That drug has seen encouraging initial sales, and management recently ...

In the last three months, 6 analysts have published ratings on SpringWorks Therapeutics (NASDAQ:SWTX), offering a diverse range of perspectives from bullish to bearish. The table below provides a ...

Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...

An error has occurred. Please try again. With a Lewiston Sun Journal subscription, you can gift 5 articles each month. It looks like you do not have any active ...